Int. J. Radiation Oncology Biol. Phys., Vol. 41, No. 4, pp. 1199–1202, 1998
Copyright © 1998 Elsevier Science Inc.
Printed in the USA. All rights reserved
PII S0360-3016(98)00000-0

AUTHOR INDEX

Abrams, R. A., 59
Acimovic, L., 161
Adamietz, I. A., 959
Agarwala, S., 581
Agboola, O., 155
Ahles, T. A., 1105
Ahrens, S., 379
Ahrnes, S., 1001
Akine, Y., 989
Akiyama, N., 913
Alberto, P., 487
Aleksandrovic, J., 161
Alexander, E., III, 573
Amdur, R. J., 1105
Amer, M. H., 91
Ames, M. M., 969
Anderson, B., 1049
Anderson, L., 325
Anderson, R. F., 827
Andrejevic-Blant, S., 403
Anscher, M. S., 73
Antell, A., 495
Antich, P. P., 747
Antoine, J. E., 299
Antolak, J. A., 661
Antonuk, L. E., 437
Arcangeli, G., 1119, 1119
Arnold, S. M., 607
Arthur, D. W., 1178
Asbell, S. O., 263
Atkinson, K., 1033
Averette, H. E., 1015
Ayene, I. S., 769

Bagniewki, P. J., 969
Baillet, F., 179
Bakri, Y., 91
Balch, C. S., 289
Ballinger, J. R., 737
Ballo, M. T., 1007
Banks, D. A., 223
Barker, B. R., 747
Barnett, G. H., 981
Bartelink, H., 247, 525
Barthel, T., 397
Battista, J., 277
Bauer, C., 1085
Bauman, G. S., 313, 319
Becker, A., 35
Bedford, J. L., 673
Benedict, S. H., 431
Benoit, B., 155
Bensadoun, R.-J., 237
Bentel, G., 1
Bentel, G. C., 73
Bergstrom, P., 305
Berkey, B., 1069
Bernhard, E. J., 769
Bey, P., 935
Biaglow, J., 833
Biaglow, J. E., 769, 871
Biert, J., 623
Biete, A., 191
Bilsky, M., 391
Bishop, K., 807
Black, P. McL., 573
Blasko, J. C., 1063
Bloching, M., 35
Bloomer, W. D., 775
Boissel, P., 935
Boisserie, G., 179
Bolek, T. W., 147
Bolla, M., 487
Bonnaud, G., 21
Bonner, J. A., 921
Bosch, W. R., 213
Böttcher, H. D., 959
Bourdin, S., 237
Bova, F. J., 591
Boxwala, A. A., 455
Brady, L., 361
Brady, L. W., 1177
Brambilla, C., 487
Brauers, G., 731
Braun, R. D., 723, 855
Braylan, R. C., 147
Breidahl, T., 891
Breithardt, G., 617
Brem, H., 631
Bright, S. J., 817
Brown, S. L., 789
Buatti, J. M., 147, 591
Buchsbaum, D. J., 817
Buckner, J. C., 969
Buller, R. E., 1049
Bundy, B. N., 1015
Burke, M. D., 763
Bush, D. A., 299
Byhardt, R., 263
Byhardt, R. W., 469

Campion, J.-P., 29
Cance, W., 345
Candeias, L. P., 917
Cantor, A., 257
Cao, L., 909
Caral, L., 977
Cardinale, R. M., 431
Carter, J., 1033
Cascino, T. L., 969
Casey, L., 257
Cellini, N., 65
Chance, B., 871
Chaney, E. L., 455
Chao, C., 335
Chao, K. S. C., 681
Chao, K. S. Clifford, 1077
Chaplin, D. J., 731, 849
Chapman, J. D., 741
Chapman, W. B., 331
Chappell, R. J., 1025
Chauvel, P., 237
Chen, H.-C., 541
Cheng, A., 213
Cheng, E. C., 11
Chevret, S., 21
Childress, C. H., 661
Chotin, G., 21
Chou, S.-C., 727
Christianson, T. J. H., 921
Christodoulou, D., 795
Clark, J., 345
Clifford, S., 1063
Cloutier, D. A., 1097
Coad, T., 277
Coche-Dequeant, B., 237
Coffin, D., 839
Cohen, A. M., 51, 325
Cohen, B. H., 981
Coia, L. R., 43, 1069
Colas-Linhart, N., 179
Coleman, C. N., 507, 781
Collingridge, D. R., 731
Collins, J. M., 289
Comack, R., 507
Connelly, P., 1015
Conroy, T., 935
Constantinescu, A., 747
Constine, L. S., 885
Cook, J. A., 795
Cooke, A. L., 117
Cooper, H. S., 43
Cooper, J. S., 1069
Corn, B. W., 101, 501
Cottrill, C. P., 807
Courdi, A., 237
Cowan, D. S. M., 905
Cox, J. D., 479
Cross, P., 155
Cummings, B. J., 331
Curiel, D. T., 817

Da Silva, V., 155
D'Agostino, R. B., Jr., 101
Dagovic, A., 1091
Dalrymple, C., 1033
D'Amico, A. V., 507
D'Angelo, L., 1119
Dar, A. R., 313
Dardoufas, K., 551
Das, I. J., 11
Dassonville, O., 237
Daşu, A., 705
Dawson, L. A., 1155
Dayal, Y., 269
D'Costa, I., 1033
De Jaeger, K., 717
De Nijs, R., 525
Dearnaley, D. P., 673
Debus, J., 995
DeGraff, W., 795
del Charco, J. O., 147
Delaney, T. F., 611
Delattre, J.-Y., 179
DeLuca, A. M., 839
Demard, F., 237
Dempsey, J. F., 421
Denekamp, J., 705
Deppe, G., 1015
DeVol, E. B., 91
Dewhirst, M. W., 723, 855, 871
Dillehay, L. E., 631
Ding, I., 885
Dobrowsky, E., 803
Dobrowsky, W., 803
Donaldson, S. S., 125
Dorszewski, A., 617
Douglass, H. O., Jr., 269
Downes, S., 385
Dray, M., 21
Driever, P. H., 959
Drzymala, R. E., 1, 1163
Dunst, J., 35, 379, 1001
Durand, R. E., 711
Durdux, C., 21
Duval, P., 1033

Edwards, B., 731
Ehrnrooth, E., 895
Eisenberg, B. L., 43
Elliott, P., 1033
Ellis, T. L., 591
El-Mohri, Y., 437
El-Senoussi, M., 91
Emami, B., 263, 469
Engel, C. J., 319
Engelhardt, E. L., 741
Engelholm, S. A., 1041
Enker, W. E., 325
Eriksson, T. B., 1147
Esche, B., 155
Essig, M., 995
Etienne, M.-C., 237
Eulert, J., 397
Evans, S. M., 871

Fang, F.-M., 541
Feelisch, M., 795
Feig, B. W., 563
Fernández-Checa, J. C., 191
Fessi, H., 179
Finkelstein, J. N., 885
Firth, I., 1033
Fisher, B., 469
Fisher, B. J., 117, 319
Fisher, C., 811
Fisher, S. G., 557
Fleming, Y., 641
Flentje, M., 397
Flickinger, J. C., 581
Folkes, L. K., 917
Fontolliet, C., 403
Fossella, F. V., 479
Fowble, B., 11, 105
Fowler, A., 1033
Fraass, B. A., 137, 651
Franssen, E., 1155
Freedman, G., 11, 105
Friedman, C. P., 455
Friedman, W. A., 591
Fritsch, D. S., 455
Fu, K. K., 1069
Fukunaga-Johnson, N., 143
Fuss, M., 995
Fyles, A. W., 717, 751

Gaballa, H. E., 431
Galakatos, A., 335
Gallup, D. G., 79
Gamson, J., 795
Garipagaoglu, M., 335
Gaspar, L. E., 263
Gelblum, D. Y., 391
Gerber, R. L., 681
Gerweck, L. E., 611
Giannarelli, D., 1119
Gil, M., 977
Gilula, L., 125
Giovinazzo, G., 1119
Glicksman, A., 125
Glickson, J. D., 871
Glisson, B. S., 479
Goldberg, Z. I., 331
Goldstein, L. J., 105
Goldwein, J. W., 143
Gomella, L. G., 501
Gonsalves, C., 155
Goodman, R., 361
Goswitz, M. S., 563
Grado, G. L., 289
Grado, M. M., 289
Graham, M., 345
Graham, M. V., 1
Grasl, C., 803
Graus, F., 977
Gray, A., 601
Grecula, J., 1085
Greven, K. M., 101
Griffin, R. J., 865
Griffin, T. W., 1063
Griffiths, L., 877
Grigsby, P. W., 335
Grimm, P. D., 1063
Grizzle, W. E., 817
Groves, E., 811
Gu, X.-Z., 929
Guarneri, E. M., 1097
Guillem, J., 325
Guillem, J. G., 51
Guillemin, F., 935
Gunderson, L. L., 351
Guo, G. Z., 785
Gwede, C., 257
Gynecology Tumor Group, the, 87

Hacke, W., 995
Hackl, A., 531
Hahn, E. W., 747
Hahn, S. M., 839
Hall, E. J., 695
Halle, J., 345
Haller, D. G., 269
Hanlon, A. L., 43, 105
Hänsgen, G., 35
Harms, D., 379
Harrison, L. B., 325
Hart, A. A. M., 247, 525
Harvey, E., 811
Hassounah, M., 601
Haughey, B., 1077
Hedley, D., 717
Held, K., 833
Hendriks, T., 623
Henk, J. M., 807
Hennequin, C., 21
Heresbach, D., 29
Hicks, K. O., 641
Hilgers, F. J. M., 247
Hill, R. P., 717, 751
Hill, S. A., 731
Hillmann, A., 1001
Hinson, J., 269
Hiraoka, M., 785, 913
Hirose, T., 351
Hirsch, A., 21
Hoffman, J. P., 43, 105
Hofman, J., 1001
Homasson, J.-P., 21
Honess, D. J., 731
Hong, W. K., 479
Hoogenhout, J., 623
Hoppe, R. T., 365
Horan, A. M., 833
Horenblas, S., 525
Hori, H., 799
Horsman, M. R., 701, 727, 891, 895
Hsi, R. A., 495
Huang, D.-D., 1133
Huang, E.-Y., 541
Huang, G.-J., 929
Huang, W., 437
Hunjan, S., 747
Hussey, D. H., 1049

Igrutinovic, I., 161
Ikeda, H., 989
Inagaki, J., 1127
Inayama, S., 799
Inomata, T., 799
Ismail, M., 501
Iwata, H., 1127
Iyer, R. V., 741

Jani, S., 1097
Jee, K.-W., 437
Jenkin, D., 601
Jenkins., W. T., 871
Jensen, P. T., 1041
Jeremic, B., 161, 1091
Ji, M., 775
Joensuu, H., 373
Johnson, D. J., 257
Jürgens, H., 379, 1001

Kachur, A. V., 769
Kagami, Y., 989
Kagan, A. R., 223
Kaiser, U. B., 573
Kaminsky-Forrett, M.-C., 935
Kanaan, I., 601
Kancharla, S., 817
Kantor, G., 361
Kapp, D. S., 531
Kapp, K. S., 531
Karlsson, E., 1147
Karnitz, L. M., 921
Kasai, S., 799
Katagiri, H., 1127
Kavanagh, B. D., 1178
Kavanagh, M.-C., 717
Kedar, A., 147
Kelleher, D. K., 843, 861
Kessler, M. L., 651
Keus, R. B., 247
Khafaga, Y., 601
Khoo, V. S., 673
Kim, J. H., 789
Kim, S., 795
Kim, S. H., 789
Kinashi, Y., 823
Kinsella, T. J., 205
Kirkwood, J., 269
Kirkwood, J. M., 581
Klamut, H. J., 331
Klein, E. E., 1163
Knelles, D., 397
Knöös, T., 1169
Kobayashi, H., 1127
Koch, C. J., 641, 769, 833
Kocha, W. I., 319
Kölbl, O., 397
Kolitsi, G., 551
Komaki, R., 263, 469, 479
Kondziolka, D., 581
Kooy, H. M., 507
Kramer, C. A., 607
Kriegshauser, J. S., 289
Krishna, C. M., 839
Kristensen, I., 1169
Kumar, S., 507
Kupelian, P. A., 981
Kuwasaka, H., 799
Kwa, S. L. S., 1
Kyprianou, K., 551

Ladekarl, M., 895
Lagrange, J.-L., 237
Lahousen, M., 531
Lamproglou, I., 179
Lanciano, R., 43
Lanciano, R. M., 101
Lanzen, J. L., 723, 855
Lapeyre, M., 935
Larson, T. R., 289
Lash, K. L., 651
Launois, B., 29
Laurie, F., 125
Lautenschläger, C., 35
Lawton, C., 469
Le, D., 747
Lebesque, J. V., 1
Lee, C. G., 73
Lee, D.-J., 811
Lee, H., 391
Lee, J. H., 143
Lee, J. S., 469, 479
Lee, W. R., 1069
Leeper, D., 871
Lehnert, S. M., 413
Leigh, B., 1055
Leon, M. B., 1097
Leone, M., 65
Leopold, K. A., 1105
Lesiuk, H., 155
Lessin, S., 361
Leung, S. W., 541
Lewis, P., 1055
Li, A. E., 905
Li, L., 899
Lichter, A. S., 1, 137, 651
Link, M. P., 125
Littbrand, B., 705
Lloyd, D. K., 413
Lockett, M. A., 335, 1077
Loeffler, J. S., 573
Löfroth, P.-O., 305
Lohr, F., 995
Longford, S., 391
Loredo, L. N., 299
Low, D. A., 213, 229, 681
Lunsford, L. D., 581
Luporsi, E., 935
Luse, R., 1063
Luzi, S., 65
Lyons, M. K., 953

Mac Manus, M. P., 365
Mackie, T. R., 205
MacLeod, C., 1033
Magdelenat, H., 179
Mah, K., 1155
Manevich, Y., 769, 833, 871
Mannel, R., 1015
Manning, J., 125
Manoux, D., 21
Mantello, G., 65
Maolinbay, M., 437
Marcial, V., 1069
Marcus, K., 1113
Marcus, R. B., Jr., 147, 591
Marcy, P.-Y., 237
Maria, B. L., 147
Marks, L. B., 1
Marks, R. S., 969
Marsh, L. H., 137
Martel, M. K., 1
Martin, E. W., 545
Martin, R. F., 827
Martínez, A., 977
Martínez-Monge, R., 545, 1085
Mason, K. A., 1137
Mason, R. P., 747
Massullo, V., 1097
Masunaga, S., 823
Matrone, G. M., 651
Mattiucci, G. C., 65
Mauch, P. M., 1113
Maxwell, R. J., 891
Maylin, C., 21
Mayo, M. S., 817
Mayo, W., 179
Mayr, N. A., 1049
McCollough, W. M., 147
McKenna, W. G., 769
McKeown, S. R., 763
McNeil, E., 143
McNutt, T. R., 205
McShan, D. L., 651
Meeks, S. L., 591
Melo, T., 737, 755
Mendenhall, N. P., 147
Mendenhall, W. M., 591
Mercke, C., 1147
Merlo, F. M., 717
Mermillod, B., 487
Meunier, B., 29
Meyn, R. E., 185

Micaily, B., 361
Michalski, J. M., 213
Michel, G., 487
Micheli, A., 1119
Micke, O., 617
Mickle, J. P., 147, 591
Milano, G., 237
Milicic, B., 161, 1091
Milisavljevic, S., 161, 1091
Millesi, W., 803
Milosevic, M., 751
Minsky, B. D., 51, 325
Mintz, G. S., 1097
Mirabell, R., 487
Miranda, M., 191
Mirimanoff, R.-O., 487
Misra, V., 755
Mitchell, J. B., 795, 839
Mitsumori, M., 573
Miyamoto, C., 361
Mohan, D. S., 981
Mohan, R., 431
Monnier, P., 403
Montana, G. S., 79
Moonen, L., 525
Moore, D. H., 79
Morales, A., 191
Moreno, V., 977
Morgan, T. L., 223
Morganti, A. G., 65
Mori, Y., 581
Moro, D., 487
Morton, G., 1155
Mose, S., 959
Mott, L. A., 1105
Motterlini, R., 849
Movsas, B., 43
Muhonen, T., 373
Mulholland, S. G., 501
Munley, M. T., 1
Munn, R. K., 607
Murayama, S., 989
Mutch, D., 335
Mutic, S., 229, 681
Muzyczka, N., 909
Mychalczak, B., 325

Nag, S., 545, 1085
Nagasawa, H., 799
Nagata, Y., 785
Nakayama, H., 989
Narayana, A., 557
Naudé, J., 803
Navickis, R. J., 289
Neff, J., 125
Nicolatou, O., 551
Nielsen, F. U., 891
Nikolic, N., 161, 1091
Nilsson, P., 1169
Nishioka, A., 799
Nisi, K., 953
Noda, M., 913
Nomura, K., 989
Nyandoto, P., 373

Oetzel, D., 1
Ogawa, Y., 799
Okajima, K., 865
Okunieff, P., 885
Olsen, C. C., 817
Olt, G., 79
Ong, A. L., 855
Ono, K., 823
Opeitum, A., 117
Ortiz, H., 1069
Oshodani, T., 799
Overgaard, J., 895
Oxman, T. E., 1105
Oya, N., 785

Paliwal, B. R., 205
Papadopoulou, M. V., 775
Parliament, M. B., 263
Patchefsky, A., 105
Patel, M. M., 1077
Patrick, T. J., 421
Patterson, L. H., 763
Paty, P. B., 325
Paty, P. P., 51
Paulussen, M., 379, 1001
Pavelka, R., 803
Pearlman, J., 257
Peiffert, D., 935
Perderau, B., 179
Perera, F. E., 117, 319
Perez, C. A., 213, 335, 681, 1077
Perret, M., 21
Peschke, P., 747
Petereit, D. G., 1025
Petersen, R. O., 501
Pettaway, C. A., 517
Phan, J. L., 981
Phillips, T. L., 1055
Pickel, H., 531
Pinilla, J., 87
Pinola, C., 391
Pintilie, M., 751
Pisters, P. W. T., 563
Pivot, X., 237
Plewes, E. A., 319
Poissonnet, G., 237
Pollack, A., 517, 563, 661, 1007
Pollock, R. A., 563
Poole, B. A., 849
Popma, J. J., 1097
Poschauko, J., 531
Powell, N. A., 731
Prevost, B., 237
Prisé, E. L., 29
Prise, V. E., 849
Provins, S., 43
Puisieux, F., 179
Purdy, J. A., 1, 205, 213, 681, 1163

Radany, E. H., 137
Radwan, J. S., 313
Ragde, H., 1063
Rainer Bowie, C. A., 365
Rajkumar, S. V., 969
Raleigh, J. A., 727
Raleigh, S. M., 763
Ralston, A., 385
Raoul, J.-L., 29
Raunecker, F., 397
Rauth, A. M., 331, 737, 755
Reddy, S. P., 557
Regine, W. F., 59
Reichel, M., 803
Reid, J. M., 969
Reinus, W., 125
Reyes-Molyneux, N. J., 299
Richardson, G. E., 573
Ritter, M. A., 205
Roach, M., 263
Roach, M., III, 1055
Robbins, H. I., 1177
Robertson, P., 143
Rodriguez-Villalba, S., 1085
Roed, H., 1041
Rojiani, A., 899
Rook, A., 361
Rose, P. G., 1015
Rosen, I. I., 661
Rosendal, F., 1041
Rosenman, J., 345
Rosenman, J. G., 455
Rossi, C. J., Jr., 299
Rostock, R., 811
Rotman, M., 1069
Rübe, C., 379, 1001
Rubin, P., 885
Ruifrok, A. C. C., 1137
Russell, A. H., 263
Russo, R. J., 1097
Ryan, L. M., 269

Sánchez-Reyes, A., 191
Sandler, H., 437
Sandler, H. M., 137, 143
Santini, J., 237
Saracino, B., 1119
Saran, F. H., 959
Sarkaria, J. N., 1025
Sasai, K., 785, 913
Sauder, B., 257
Sause, W. T., 469
Saxer, A., 79
Scarpine, V. E., 437
Schäfer, U., 617
Schatz, R. A., 1097
Scheithauer, B. W., 351, 953
Scher, R. M., 43
Schild, S. E., 351, 953
Schmidt-Ullrich, K., 1178
Schneider, M., 237
Schneider, R. F., 741
Schomberg, P. J., 953, 969
Schuck, A., 1001
Schuller, D. E., 1085
Schulte, R. W. M., 299
Schultz, D. J., 495
Schutt, A. J., 269
Scott, C., 469
Scott, C. B., 263
Seaward, S. A., 1055
Seifert, W. F., 623
Sessions, D., 1077
Shabanah, M. Al., 601
Sham, E., 711
Sharpe, G., 959
Shastri, V. R., 631
Shaw, E. G., 953
Shibamoto, Y., 161, 1091
Shibata, T., 785, 913
Shibui, S., 989
Shibuya, K., 785
Shrieve, D. C., 573
Shulman, L. N., 1113
Shuster, J. J., 125
Siemann, D. W., 697, 899, 909
Siewerdsen, J. H., 437
Sigurdson, E. R., 43, 105
Siim, B. G., 641, 905
Simpson, J. R., 1077
Sischy, B., 269
Skarlatos, J., 551
Skwarchuk, M. W., 169
Slater, J. D., 299
Slater, J. M., 299
Smith, T. J., 269
Solin, L. J., 495
Song, C. W., 865
Sorosky, J. I., 1049
Sotiropoulou-Lontou, A., 551
Spahn, U., 1
Spector, G. J., 1077
Spencer, S., 811
Stackhouse, M. A., 817
Steeves, R. A., 1177
Steinvorth, S., 995
Steuterman, S., 1097
Stevens, C., 871
Stevens, G., 385
Stitt, L., 117, 277
Stitt, L. W., 319
Stobbe, C. C., 741
Stødkilde-Jorgensen, H., 891
Storen, E., 1113
Stratford, I. J., 877
Stubbs, J. B., 421
Stuecklschweiger, G. F., 531
Suchindran, S., 727
Sugiura, H., 1127
Suh, J. H., 981
Sumi, M., 989
Sun, L.-M., 541
Suwinski, R., 943
Suwinsky, R., 463
Suzuki, M., 823
Swanson, G. P., 289
Swift, M., 1133
Sylvester, J., 1063

Tables, L., 727
Taghian, A., 464
Tai, P., 277
Takagaki, M., 823
Takahashi, M., 1127
Tanaka, M., 989
Tapen, E. M., 1063
Tarbell, N. J., 1113
Taylor, J. M. G., 943
Taylor, M., 319
Teichman, S. L., 299
Teirstein, P. S., 1097
Teissier, E., 237
Tempany, C. M., 507
Ten Haken, R. K., 1, 137
Teschendorf, C., 909
Tetteh Ago, C., 313
Thames, H. D., 1137

Theuws, J. C. M., 1
Thews, O., 843, 861
Thilmann, C., 959
Thomadsen, B. R., 205
Thomas, G. M., 79
Thompson, E., 125
Thyss, A., 237
Tinger, A., 213
Tokuuye, K., 989
Topulos, G., 507
Tormey, D. C., 269
Torrey, M., 125
Tozer, G. M., 849
Travis, E. L., 169
Tredaniel, J., 21
Tripuraneni, P., 1097
Trotti, A., 257, 811
Tuttle, S., 833
Tuttle, S. W., 769, 871

Valentini, V., 65
Valicenti, R. K., 501
Valliconi, J., 237
van den Bergh, H., 403
van der Voet, J. C. M., 247
Van Dyk, J., 277
Varia, M. A., 727, 1015
Vaughan, A. T. M., 557
Vaupel, P., 843, 861
Venkatesan, V. M., 313
Verger, E., 977
Verhofstad, A. A. J., 623
Videtic, G. M. M., 319
Vikram, B., 1069
Villa, S., 977
Vincent, M. D., 319
Viñolas, N., 977
Vlachaki, M. T., 185
Voet, H. V. D., 525
Volkman, S. K., 651
von Roemeling, R., 811
Vonderheid, E. C., 361
Vroman, B. T., 921

Wagman, R., 51
Wagnieres, G., 403
Waites, A., 705
Walch, S., 1105
Wallner, K., 391
Walton, M. I., 807
Wang, C.-J., 541
Wang, S.-J., 541
Wang, X., 885
Wannenmacher, M., 995
Wanogho, E., 763
Wardman, P., 917
Warrington, K. H., Jr., 909
Webb, S., 673
Weidner, G. J., 1049
Weigel, C., 35
Weil, M., 1137
Weinberg, V., 1055
Weiner, L. M., 43
Weissberg, J. B., 1133
Wenz, F., 995
West, C., 1147
Westfall, L. A., 1163
White, C., 325
Widder, J., 803
Widmark, A., 305
Wiegand-Packard, L., 1105
Wildermuth, S., 995
Wilkes, M. M., 289
Williams, J. A., 421, 631
Williams, J. R., 631
Williams, R., 1163
Williamson, J. F., 421
Willich, N., 617, 1001
Wilson, J., 849
Wilson, P., 959
Wilson, W. R., 641, 905
Wink, D. A., 795
Winkelmann, W., 379
Winquist, E. W., 313
Withers, H. R., 235, 463, 943
Wobbes, T., 623
Wong, P. S., 747
Wong, W. W., 351, 953
Woodtli, A., 403
Wroblewski, K., 871
Wu, Q., 431

Yamamura, S., 1127
Yang, C.-W., 541
Yapp, D. T. T., 413
Yaya, R., 977
Yin, W.-B., 929
Yonemoto, L. T., 299
Yorkston, J., 437
Yoshida, S., 799
Yu, E., 277
Yuan, X., 631

Zagars, G. K., 517, 563, 661, 1007
Zaidi, S. T., 611
Zhang, D.-W., 929
Zhang, R.-G., 929
Zhang, X., 737
Zhang, Z.-X., 929
Zhen, W., 1049
Zhou, S.-M., 73
Zhu, J., 413
Zhu, R., 213
Zoubek, A., 379
Zwicker, R. D., 431

Int. J. Radiation Oncology Biol. Phys., Vol. 41, No. 5, pp. 1203–1205, 1998
Copyright © 1998 Elsevier Science Inc.
Printed in the USA. All rights reserved
PII S0360-3016(98)00000-0

SUBJECT INDEX

A

AAV, 909
Accelerated hyperfractionation, 803
Active matrix flat-panel imager, 437
Acute myelogenous leukemia, 1113
ADEPT, 917
adjuvant radiation, 101
Adjuvant therapy, 51
Advanced uterine cancer, 1041
Advanced vulvar cancer, 79
Adverse effects, 373
aFGF, 885
Age, 977
Age at presentation, 959
Anal canal carcinoma, 331
Anaplastic astrocytoma, 969
Anemia, 1069
Anesthesia risk, 1049
Angiogenesis, 877
Animal model, 617
Antimetastasis, 799
Antioxidants, 191
Antivascular agent, 905
Anxiety, 1105
Apoptosis, 185
AQ4N, 763
Arteriovenous malformation (AVM), 995
Artery radiation effects, 617
Ataxia-telangiectasia, 1133
Attention, 995
Automated treatment delivery, 651
Azomycin nucleoside, 741

B

B.i.d. radiotherapy, 237
B6, 169
Bcl-2 oncogene, 185
BCNU, 969
bFGF, 885
Biodegradable polymer, 413, 631
Biological response modifier, 799
Bioreduction, 755, 763
Bioreductive drugs, 641, 775, 909
Bladder cancer, 525
^{99m}BnAO, 737
Bone metastases, 1119
bone metastasis, 161
Brachytherapy, 87, 101, 289, 545, 1033, 1041, 1049, 1063
Brain metastases, 155
Brain metastasis, 581
Brain neoplasm, 421
Brain neoplasms, 591
Brain tumors, 137, 969
Breast, 11
Breast cancer, 105, 117, 495
Breast preservation, 345
BSH, 823

C

C3H, 169
C3H mouse mammary carcinoma, 895
Camptothecin, 785
Cancer, 1105
Cancer of the esophagus, 277
Carbogen, 855
Carbogen breathing, 865
Carbon monoxide, 849
Carcinogenesis, 385
Cardiac adenocarcinoma, 929
Cardiac effect, 11
Cell kinetics, 711
Cellular respiration rate, 843
Cervical cancer, 541, 1025, 1049
Cervical carcinoma, 531, 1015
Cervix carcinoma, 751
Cervix-neoplasm, 91
Chemoradiation, 79, 1015
Chemotherapeutic agents, 775
Chemotherapy, 29, 365, 373, 379, 479, 487, 969, 1091, 1127
Chemotherapy introduction, 953
Chest wall recurrence, 495
Childhood cancer, 379
Childhood leukemia, 385
Cisplatin, 79, 413, 479, 969, 1015
clinical presentation, 91
Clinical radiotherapy, 705
Clinical results, 573
Colorectal adenocarcinoma, 545
Combined modality, 487
Combined treatment, 29, 929
Combined-modality therapy, 1077
Combretastatin, 891, 899
Combretastatin A-4 disodium phosphate, 895
Complications, 247, 391, 1025
Compression, 607
Computer control, 651
Computer simulation, 705
Computer-assisted radiotherapy, 591
Computer-assisted radiotherapy planning, 591
Concurrent, 479
Concurrent Chemoradiation, 470
Conformal radiotherapy, 673
Conformal therapy, 651, 1169
Conformity index, 1169
Conservation therapy, 335
Conservative surgery, 105
Contrast-detail study, 437
Cord, 607
CPT-11, 785
Craniopharyngioma, 601
CYP 1A, 763
CYP 2C, 763
CYP 2D, 763
CYP 3A, 763
Cysteine, 833
Cytokines, 169

D

Depression, 1105
Desmoid tumor, 1007
Detective quantum efficiency, 437
Diagnostic, 737
digital portal images, 455
DMXAA, 905
Dose escalation, 137
Dose modification, 413
Dose-escalation, 305
Dose–volume histogram, 1, 65, 507
Dose-response, 943
Dosimetry, 385, 421
downstaging, 43, 935
DT-diaphorase, 331

E

Early glottic cancer, 247
Economic analysis, 87
EF5, 641
EGF, 1137
EGF-R, 1137
Elderly patients, 981
Electron beam, 1085
Electronic portal imager, 437
Electroporation, 823
Endobronchial brachytherapy, 21
Endometrial cancer, 101, 1033, 1049
Endometrial neoplasms, 87
Enzyme-prodrug therapy, 917
Ependymoma, 953
Eppendorf histograph, 895
Errors, 651
Erythropoietin, 913
Esophageal carcinoma, 29
Etanidazole, 1069
Etoposide, 969
Ewing's sarcoma, 125, 379, 1001
Extended field radiation, 1015
Extravascular diffusion, 641

F

^{19}F NMR, 747
Failure patterns, 470
Field localization errors, 223
5-Fluorouracil, 79, 319, 1015
Flavin adenine dinucleotide, 871
Flow redistribution, 861
Fluorescence, 871
Follicular, 365
Fractionated radiation, 413
Fractionated radiotherapy, 905
Fractionation, 247, 705
Free radicals, 839

G

Gene therapy, 755, 817
Gleason score, 1055
Glioblastoma, 969
Glioblastoma multiforme, 981
Glioma, 421
Glutathione, 185, 769, 833
GM-CSF, 551
Granulocyte–colony-stimulating factor (G-CSF), 1113
GSH, 191

H

Haemoxygenase, 849
Hamster, 403
HDR brachytherapy, 541, 1025
Head neck carcinoma, 811, 1069
Head neck neoplasms-radiotherapy, 257
Head neck tumors, 35, 1085
Heart volume, 11
Hemoglobin, 35
Heterotopic ossification, 397
Heterozygotes, 1133
Hexafluorobenzene, 747
High dose rate, 325
High precision conformal radiotherapy (HPCRT), 305
High risk, 1055
High-dose-rate, 1033
High-dose-rate brachytherapy, 531
HL-91, 737
Hodgkin's disease, 373
Human glioma, 631
Human squamous cell carcinoma, 921
Human tumor cell lines, 1147
Human tumors, 1147
Hydrogen peroxide, 769
Hyperfractionated radiation therapy, 479
Hyperfractionation, 470
Hypopharynx carcinoma, 237
Hypotension, 839
Hypoxia, 35, 641, 705, 711, 723, 737, 747, 751, 755, 763, 795, 843, 913
Hypoxia marker, 727
Hypoxia-inducible factor 1, 913
Hypoxia-reoxygenation, 723
Hypoxia-responsive element, 913
Hypoxic cell radiosensitizer, 799
Hypoxic cell sensitizer, 1069
Hypoxic cytotoxin, 811
Hypoxic marker, 741
hypoxic-specific factor, 741

I

^{125}I, 421
IFN, 885
IGF, 885
image analysis, 455
Implant, 507
Indole-3-acetic acids, 917
Inoperable endometrial cancer, 1025
Inoperable lung cancer, 487
Intensity modulated radiation therapy, 229
Intensity modulation, 431
Intensity-modulated radiation therapy, 681
Interferon, 611
Interstitial photodynamic therapy, 403
Intestine, 169
Intimal hyperplasia, 617
Intracavitary brachytherapy, 421
intracavitary therapy, 91
Intraoperative, 1085
Intraoperative radiation therapy, 325
Intratumoral delivery, 413
Intrinsic radiosensitivity, 705
Iodine, 289, 545
Iodine-125, 1063
Iododeoxyuridine, 631
Ipsilateral breast tumor recurrence, 105
Irradiation, 335, 747, 1077
Isoeffective doses, 137

K

KHT sarcoma, 899

L

Laminaria, 1049
Laryngeal cancer, 557
Larynx preservation, 247
Late effects, 21, 1041
L-buthionine-SR-sulfoximine, 833
LDF, 885
Learning, 179
Leukemia, 379
Lidocaine, 541
Light delivery, 403
LINAC, 573
Liposarcoma, 563
Local control, 1001
Local electron beam irradiation, 361
Locally advanced breast cancer, 345
Local-regional recurrence, 117
Locoregional control, 247
Locoregional recurrence, 335
Low-dose rate irradiation, 1147
Low-grade, 365
Lung, 1
Lung volume, 11
Lymphoma, 185, 365

M

Magnetic resonance imaging, 507, 891
Magnetic resonance spectroscopy, 891
Malignant fibrous histiocytoma, 563
Malignant glioma, 977
Malignant melanoma, 581
Malignant peripheral nerve sheath tumor, 351
Mean dose, 1
Mechanism, 755
Medulloblastoma, 143, 147, 959
MEK Erk protein kinases, 921
Memory, 995
Meta-iodobenzylguanidine (MIBG), 871
Metallothionein, 727
Methylene blue, 769
Methylxanthine derivatives, 861
Microcirculation, 843
Microvascular O_2 content, 843
Mild hyperthermia, 865
Mitomycin C, 331, 803
Modulation of O_2 supply, 843
Morbidity, 391, 1025
morbidity mortality, 91
Mortality, 1025
Mouse jejunum, 1137
MPNST, 351
Multicellular layers, 641
Multidisciplinary therapy, 125
Multivariate analysis, 21
Murine, 839

N

N-acetyl-cysteine, 833
NAD(P)H, 871
NADPH, 769
Neurofibrosarcoma, 351
Neurogenic sarcoma, 351
Neurological status, 1127
Neuropsychology, 995
New radiotherapy technique, 305
9L Glioma tumor, 871
Nitric oxide, 795, 849
Nitroxide, 839
Nitroxyl, 795
NLCQ-1, 775
Non-small cell lung cancer, 479, 487
Nonsmall-cell lung cancer, 263, 1091
Nonsteroidal anti-inflammatory drugs, 397
Normal tissue complication probability, 1
Normal tissue tolerance, 989
NQO1, 909

O

O_2 availability, 843
observer studies, 455
Oral Etoposide, 479
Oral mucositis, 551
Organ motion, 213
Organ preservation, 51
Oropharynx carcinoma, 237
Osmotic cervical dilation, 1049
Osmotic pumps, 413
Oxidation therapy, 917
Oxidative stress, 191
Oxygen, 855
Oxygen consumption, 871
Oxygen tension, 747
Oxygenation strategies, 843

P

p185^{erbB-2}, 817
p53, 557
pain relief, 161, 1119
Palladium, 289
Palladium-103, 1063
Palliative radiotherapy, 1119
Para-aortic node metastases, 1015
Paraortic recurrence, 545
Pathology, 351
Patterns of failure, 263
Pelvic recurrence, 545
Pentoxifylline, 861
Peroxidases, 917
pH, 871
Pharmacokinetic survey, 237
Phosphotyrosyl proteins, 833
Photon dose-calculation algorithm verification, 681
Photosensitizer, 403
Pimonidazole, 727
Pituitary adenoma, 573
Planning target volume, 661, 673
Platelet-derived endothelial cell growth factor, 877
^{31}P-NMR *in vivo*, 871
pO_2, 865
POG, 125
Polarographic pO_2 measurements, 35
Polymerase chain reaction, 331
Port films, 223
Postmenopausal, 117
Postoperative irradiation, 1077
Potentiation, 775
pp59fyn kinase, 833
Preoperative irradiation, 1077
Preoperative radiation therapy, 397
Preoperative radiotherapy, 929, 935, 943
pre-operative therapy, 43
Prodrugs, 755
Prognosis, 517, 1007
prognostic factors, 91, 155, 299, 531, 935, 959, 1001
Prophylactic cranial irradiation, 385
Prospective studies, 257
Prostate, 299, 1063
Prostate cancer, 73, 213, 305, 501, 507, 517, 673, 1055, 1155
Prostate carcinoma, 65, 289
Prostate motion, 661, 1155
Prostate phantom, 205
Prostate radiotherapy, 661
Prostate-specific antigen, 289, 1055
Proton, 299
PSA, 299
Psycho-oncology, 1105
Pulmonary embolism, 1063
Pulsed dose rate, 1041

Q

Quality assurance, 205, 223, 277, 651, 1163
Quality of life, 257, 1105
Questionnaires, 257

R

R&V, 1163
Rabbits, 617
Race, 517
Radiation, 105, 169, 185, 257, 607, 611, 617, 785, 789, 795
Radiation complications, 11
Radiation dose, 501
Radiation injury, 989
Radiation pneumonitis, 1
Radiation response, 865, 921, 1137
radiation therapy, 91, 223, 263, 277, 345, 385, 495, 501, 507, 517, 531, 581, 817, 953, 969, 1007, 1055, 1091, 1127, 1133, 1163, 1169
Radiation therapy planning, 65
radiation/chemotherapy, 43
radical hysterectomy, 91
Radical prostatectomy, 501
Radioactive fluid, 421
Radiobiology, 191
Radiochemotherapy, 237, 1001
Radioprotection, 839
Radioresistance, 705
Radiosensitivity, 1133, 1147
Radiosensitization, 611, 631, 817
Radiosurgery, 581, 995
Radiotherapy, 29, 73, 125, 143, 147, 155, 213, 247, 299, 313, 319, 365, 373, 379, 421, 479, 487, 525, 551, 557, 563, 711, 789, 959, 977, 981, 1085, 1105, 1155
Rat, 179
Rats, 723
Reactive oxygen species, 833
Record verify, 651, 1163

Rectal cancer, 43, 51, 319, 325, 935, 943
recurrence rate, 91
Recurrences, 1085
Recurrent gynecologic cancer, 1041
Recursive partitioning analysis, 263
Redox scanning, 871
Relapse, 365
Relapse analysis, 1001
Reoxygenation, 751
Restenosis, 617
Retinoic acid, 611
RIF-1 mouse tumor model, 413

S

Saudi, 91
Scale development, 257
SCCVII tumor cells, 823
Second cancer, 373
Second neoplasms, 379
Second primary tumor, 557
Segmental intensity modulation, 651
Seminoma, 313
Sensitizer, 795
Single fraction radiation therapy, 161
Single-chain antibody, 817
Smooth muscle cells, 617
SN-38, 785
SOD, 179
Solid tumours, 737
Spinal, 607
Spinal metastasis, 1127
Spontaneous murine tumors, 895
squamous cancer, 91
Squamous cell carcinoma, 403
SR 4233, 811
staging, 91
Stereotactic radiosurgery, 391, 431, 573, 591
Stereotactic radiotherapy, 573, 989
Stereotaxic techniques, 591
Strain, 169
Striated muscle, 403
Subclinical disease, 943
Supportive care, 237
Surgery, 125, 147, 155, 929, 953, 977, 981
surgical treatment, 91
Survival, 470, 1127
survival outcome, 91
Synovial sarcoma, 563

T

Tamoxifen, 117
Target position variability, 1155
Target-volume definition, 277
Technetium chelate, 741
TGFβ, 885, 1137
TGF-beta, 169
Thalassemia, 607
3D Conformal, 213
3-D Conformal radiotherapy, 205
3D image registration, 661
Three-dimensional, 1169
Three-dimensional (3D) treatment planning, 277
Three-dimensional conformal radiation therapy, 65
Three-dimensional conformal radiotherapy, 73
Three-dimensional treatment planning, 137, 431
Thymidine phosphorylase, 877
Thymidylate Synthase Inhibitor, 789
Thyroid, 385
Tirapazamine, 641, 811, 905
Tissue damage, 403
TLD, 385
TNF, 885
TNF-alpha, 169
Tomotherapy, 229, 681
Tonsil, 1077
Tonsillar fossa, 1077
Topical anesthesia, 541
Topoisomerase I, 785
Total body irradiation, 179, 1113
Total hip replacement, 397
Toxicity, 470
Treatment margin, 673
Treatment planning, 73, 213, 1169
treatment results, 91
Treatment time, 525
Treatment verification, 681
Tumor, 747
Tumor blood flow, 855
Tumor growth delay, 905
Tumor hypoxia, 727, 895
Tumor necrosis, 895
Tumor oxygenation, 35, 843, 861
Tumor perfusion, 861
Tumor proliferation, 525, 943
Tumors, 723
Tumour blood flow, 849
Tumour vasculature, 891
Tumourigenicity, 877
TX-1877, 799

U

Uncertainty, 213
Unilesional mycosis fungoides, 361
Unresectable non-small cell lung cancer, 470

V

Vascular endothelial growth factor, 913
Vascular injuries, 617
Vascular targeting, 899
Virally directed enzyme/prodrug therapy, 909
Vulvar cancer, 335

W

Whole-body dose, 229
Workstation, 455

X

Xenografts, 711
X-ray, 617